$TSHA
Taysha Gene Therapies, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020053602 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.980M
YoY Change
% of Gross Profit
Research & Development $11.06M $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $15.04M $31.00K
YoY Change 48419.35%
Operating Profit -$15.04M -$31.00K
YoY Change 48419.35%
Interest Expense $1.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.000K
YoY Change
Pretax Income -$15.04M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$15.04M -$31.00K
YoY Change 48422.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$435.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $278.6M
YoY Change
Cash & Equivalents $278.6M $0.00 $0.00
Short-Term Investments
Other Short-Term Assets $600.0K
YoY Change
Inventory
Prepaid Expenses $604.0K
Receivables
Other Receivables
Total Short-Term Assets $279.2M $15.00K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $28.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $28.00K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $279.2M $15.00K
Total Long-Term Assets $28.00K $0.00
Total Assets $279.3M $15.00K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.837M
YoY Change
Accrued Expenses $2.727M $150.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $100.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.62M $150.0K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $11.62M $150.0K
Total Long-Term Liabilities $0.00
Total Liabilities $11.62M $150.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$42.81M -$1.115M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $267.6M -$135.0K $0.00
YoY Change
Total Liabilities & Shareholders Equity $279.3M $15.00K
YoY Change

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$15.04M -$31.00K
YoY Change 48422.58%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$6.710M $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$30.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 274.2M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -6.710M 0.000
Cash From Investing Activities -30.00K 0.000
Cash From Financing Activities 274.2M 0.000
Net Change In Cash 267.4M 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$6.710M $0.00
Capital Expenditures -$30.00K $0.00
Free Cash Flow -$6.680M $0.00
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
278634000
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
604000
CY2019Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
15000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
279238000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
15000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28000
CY2020Q3 us-gaap Assets
Assets
279266000
CY2019Q4 us-gaap Assets
Assets
15000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8837000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2727000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
150000
CY2020Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
60000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11624000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
150000
CY2020Q3 us-gaap Liabilities
Liabilities
11624000
CY2019Q4 us-gaap Liabilities
Liabilities
150000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
310450000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
980000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42808000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1115000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
267642000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-135000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279266000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10895000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37761435
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10894999
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37761435
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10894999
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11057000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19633000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3984000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5002000
CY2019Q3 tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
6000000
CY2019Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Share Based Compensation
ShareBasedCompensation
1341000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
15041000
us-gaap Operating Expenses
OperatingExpenses
24635000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
31000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15041000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24635000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31000
tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
-17030000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1000
us-gaap Interest Expense
InterestExpense
28000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17058000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-15042000
us-gaap Net Income Loss
NetIncomeLoss
-41693000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-31000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.73
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11733170
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-26786000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
142240000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
165889000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1341000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
15111000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
15111000
tsha Temporary Equity Stock Issuance Of Preferred Stock Tranche Liability
TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability
1050000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
142240000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
165889000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1341000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-31000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-31000
us-gaap Profit Loss
ProfitLoss
-41693000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-31000
us-gaap Depreciation
Depreciation
3000
CY2019Q3 us-gaap Depreciation
Depreciation
0
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
604000
CY2019Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5403000
CY2019Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1579000
CY2019Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
31000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
60000
CY2019Q3 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10881000
CY2019Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3000000
CY2019Q3 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000
CY2019Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3031000
CY2019Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
167162000
CY2019Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1673000
CY2019Q3 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
292546000
CY2019Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
278634000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
278634000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
us-gaap Interest Paid Net
InterestPaidNet
28000
CY2019Q3 us-gaap Interest Paid Net
InterestPaidNet
0
tsha Reclassification Of Preferred Stock Liability Upon Issuance Costs
ReclassificationOfPreferredStockLiabilityUponIssuanceCosts
18080000
CY2019Q3 tsha Reclassification Of Preferred Stock Liability Upon Issuance Costs
ReclassificationOfPreferredStockLiabilityUponIssuanceCosts
0
tsha Allocation Of Preferred Stock Tranche Liability
AllocationOfPreferredStockTrancheLiability
1050000
tsha Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
142240000
CY2019Q3 tsha Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
0
tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
3000000
CY2019Q3 tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. These estimates and assumptions are based on current facts, historical experience as well as other pertinent industry and regulatory authority information, including the potential future effects of COVID-19, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on these deposits. </p>
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15647052
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
767000
CY2019Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
7000
CY2020Q3 tsha Accrued Issuance Costs Current
AccruedIssuanceCostsCurrent
752000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
544000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
462000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
122000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
202000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
32685000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q1 tsha Preferred Stock Tranche Liability
PreferredStockTrancheLiability
1100000
CY2020Q2 tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
17000000
CY2020Q3 tsha Mile Stone Shares Issued
MileStoneSharesIssued
4000000
CY2020Q3 tsha Amount Reclassified To Convertible Preferred Stock
AmountReclassifiedToConvertiblePreferredStock
18100000
CY2020Q2 tsha Mile Stone Shares Issued
MileStoneSharesIssued
200000
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
7.52
CY2020Q3 tsha Common Stock Fair Value Per Share
CommonStockFairValuePerShare
5.28
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1341000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1341000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3804453

Files In Submission

Name View Source Status
0001564590-20-053602-index-headers.html Edgar Link pending
0001564590-20-053602-index.html Edgar Link pending
0001564590-20-053602.txt Edgar Link pending
0001564590-20-053602-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-10q_20200930.htm Edgar Link pending
tsha-20200930.xml Edgar Link completed
tsha-20200930.xsd Edgar Link pending
tsha-20200930_cal.xml Edgar Link unprocessable
tsha-20200930_def.xml Edgar Link unprocessable
tsha-20200930_lab.xml Edgar Link unprocessable
tsha-20200930_pre.xml Edgar Link unprocessable
tsha-ex107_186.htm Edgar Link pending
tsha-ex311_11.htm Edgar Link pending
tsha-ex312_10.htm Edgar Link pending
tsha-ex321_9.htm Edgar Link pending
tsha-ex322_8.htm Edgar Link pending